ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Staidson (Beijing) Biopharmaceuticals Co., Ltd clinical trials

Part of Yizhao (Beijing) Medical Science & Technology Co., Ltd., which holds 36.11% as of 2024-12-20. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 29 studies whose lead sponsor is Staidson (Beijing) Biopharmaceuticals Co., Ltd or the company grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 22, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Staidson (Beijing) Biopharmaceuticals with Hamad Medical and AstraZeneca →

Pipeline: 3 programs

Each counted once: 3 with a study Staidson (Beijing) Biopharmaceuticals Co., Ltd leads registered in the last two years.

  • Phase 2
  • Phase 3

The 2 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Staidson (Beijing) Biopharmaceuticals Co., Ltd’s own registered studies; Staidson (Beijing) Biopharmaceuticals Co., Ltd’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Staidson (Beijing) Biopharmaceuticals Co., Ltd’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

2 of Staidson (Beijing) Biopharmaceuticals Co., Ltd’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. 1A
  7. M
  8. J
  9. J
  10. A
  11. 1S
  12. O
  13. N

Add all 2 to your calendar (.ics) → With an account.

All 29 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now517%Recruiting 4 · Not yet recruiting 1
  • Completed1966%
  • Stopped early517%

Phase

  • Phase 119
  • Phase 212
  • Phase 33

Where

  • China26
  • United States3
  • Indonesia1
  • India1
  • Bangladesh1
  • Spain1

Over the years

  1. 19
  2. 20
  3. 21
  4. 22
  5. 723
  6. 24
  7. 25
  8. 126

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Staidson (Beijing) Biopharmaceuticals Co., Ltd.

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    28 studies
  • Staidson Biopharma Inc.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Studies

Recruiting first, then most recently updated. Showing 29 of 29.